ReviewFrontiers in pharmacology2025
Plant-derived natural products targeting inflammation in treatment of atherosclerosis.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biologically Active Compounds and Antioxidant and DNA-Protective Potential of Rhodope AvensMolecules (Basel, Switzerland) · 2026Article
- Targeting the NLRP3 Inflammasome in Atherosclerosis: A Review of Natural Products and Their Molecular Mechanisms.International journal of molecular sciences · 2026Review
- Targeting NF-κB Signaling with Natural Products: A Promising Therapeutic Strategy for Cardiovascular Diseases.Biomolecules · 2026Review
- Dietary Polyphenols (Flavonoids) Derived from Plants for Use in Therapeutic Health: Antioxidant Performance, ROS, Molecular Mechanisms, and Bioavailability Limitations.International journal of molecular sciences · 2026Review
- Beyond metabolism and blood flow: toward an inflammation-metabolism axis paradigm for herbal medicine in obesity-related coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- The gut-heart axis in heart failure: from bidirectional pathophysiological mechanisms to integrative therapeutic strategies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a complex and chronic inflammatory vascular disease, and it's also the pathological basis of various diseases such as coronary heart disease. Owing to their advantages such as multiple targets and rich diversity, Plant-Derived natural products with abundant resources will become an important source of anti-AS drugs. Herein, we explored the intricate association between inflammation and AS, focusing on plant-derived natural products that specifically target inflammation for the treatment of AS. This review systematically analyzes 10 plant species, focusing on 23 high-potential metabolites including Tanshinone IIA, Berberine, and Ginsenoside Rb1 et al. We found that natural products with anti-AS properties are primarily derived from plants belonging to the families Araliaceae, Umbelliferae, Fabaceae, and Lamiaceae. The chemical structures of these natural products mainly consist of flavonoids, alkaloids, saponins, and polysaccharides, among others. This suggests that natural products with different structural types can exhibit anti-AS activities, with flavonoids, alkaloids, and saponins showing greater potential. Major anti-inflammatory pathways center on NF-κB/NLRP3 inflammasome inhibition (e.g., Tan IIA, Salidroside), ROS scavenging (e.g., Danshensu, Rosmarinic acid), and endothelial protection (e.g., Astragaloside, Puerarin), while highlighting NLRP3 inflammasome inhibition and gut-microbiota modulation as emerging therapeutic avenues. These will actively promote the clinical application and industrial production of Plant Derived natural products, thereby developing anti AS drugs with excellent efficacy and reduced adverse reactions. We hope that this comprehensive review will provide valuable insights into the potential and pharmacological mechanisms of current natural medicines, thereby offering support for future drug discoveries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.